Speakers

Scott is founder and Chief Technology Officer of Kynos Therapeutics and Professor of Medicines Discovery at the University of Edinburgh. Following a period working in biotech he joined the Centre for Cardiovascular Science at the University of Edinburgh where he built a drug discovery team and led its first project from inception through to Phase I studies and out-licensing. With his university colleague, Damian Mole, his team was also part of a fruitful Discovery Partnerships with Academia collaboration (DPAc) with GSK to identify small molecule inhibitors of KMO for the treatment of acute pancreatitis. Following a strategic decision by GSK to close all DPAc programmes he and Damian formed Kynos Therapeutics where they are developing their portfolio of KMO inhibitors for the treatment of a range of acute and chronic inflammatory conditions.

Presentation Title: Manufacturing KNS366 from Spinout to First in Human Studies

Abstract: Kynos Therapeutics is a spinout company arising from a previous collaboration between the University of Edinburgh and GSK. Kynos co-founder, Prof Scott Webster, will outline the issues facing a new company to create the infrastructure required to transfer assets from large pharma and implement manufacture of drug product for intravenous administration in a Phase I clinical trial.

View company profile